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Secondary to Ibrutinib
Hani Essa, MBCHB, MRES,a Taha Lodhi, MBCHB, MRES,b Rebecca Dobson, MBCHB, HONS, MD,a
David Wright, MBCHB, MD,a Gregory Y.H. Lip, MBCHB, MDa,cA trial fibrillation (AF) is the most common car-diac arrhythmia and a significant cause ofcardiovascular morbidity and mortality
worldwide (1). Ibrutinib is a covalent irreversible in-
hibitor of Bruton’s tyrosine kinase (BTK) used in the
treatment of B-cell cancers such as chronic lympho-
cytic leukemia and mantle cell lymphoma. It is esti-
mated that up to 16% of patients develop ibrutinib-
induced AF, which can be a therapy-limiting side ef-
fect. The mechanisms are not clear but may relate to
direct inhibition of BTK, which is expressed in cardiac
tissue (2). In this primer, we use a clinical case of a
patient with chronic lymphocytic leukemia to demon-
strate the challenges and management considerations
of AF secondary to ibrutinib.
CASE PRESENTATION
A 68-year-old man with hypertension and hyperlip-
idemia presents to the hematology clinic for follow-
up of his chronic lymphocytic leukemia. He had
initially been treated with 6 cycles of cyclophospha-
mide and rituximab with a partial response. This was
subsequently followed by ibrutinib 420 mg once
daily. At his follow-up clinic appointment, he com-
plained of palpitations and intermittent shortness of
breath. His pulse was 77 beats/min and regular, his
respiratory rate was 18 breaths/min, and his blood
pressure was 137/78 mm Hg. His chest was clear, he
had normal heart sounds, and there was no evidence
of pedal edema. His electrocardiogram (ECG)ISSN 2666-0873
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axis. Laboratory investigation demonstrated a normal
hemoglobin, urea and electrolytes, bone profile, and
magnesium. He was referred to the cardiology clinic
for further management.
This patient has several risk factors for AF
including age, hypertension, and exposure to car-
diotoxic chemotherapy (cyclophosphamide and rit-
uximab) (3). We recommend a 12-lead ECG at baseline
before ibrutinib initiation. Ibrutinib treatment in-
creases his risk of AF, and it is prudent to have a high
index of suspicion for this in the context of his re-
ported palpitations. A 12-lead ECG may capture AF,
but as this case demonstrates, more prolonged
monitoring is often required. The importance of
emerging technologies such as smartwatches as
diagnostic tools to diagnose asymptomatic AF has
been demonstrated; it would be reasonable to use this
strategy for more prolonged monitoring (4). However,
not all patients own such devices. In this case, referral
to cardiology can help facilitate 72-h ambulatory ECG
monitoring and an echocardiogram. A cardiologist
with a subspecialty interest in cardio-oncology is best
placed to guide patient management.
CASE CONTINUED
The patient proceeded to have 72 h of ambulatory
ECG monitoring, which demonstrated a 10% burden
of AF with a rapid ventricular response. The patient
reported symptoms of palpitations and shortness ofhttps://doi.org/10.1016/j.jaccao.2020.11.016
rpool, Liverpool Heart & Chest Hospital, Liverpool,
t, Manchester, United Kingdom; and the cAalborg
rsity, Aalborg, Denmark.
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
mber 22, 2020, accepted November 25, 2020.
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial fibrillation
BTK = Bruton’s tyrosine kinase
DOAC = direct oral
anticoagulant
ECG = electrocardiogram
LMWH = low molecular weight
heparin
OR = odds ratio
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141breath that coincided with these events. His trans-
thoracic echocardiogram demonstrated a moderately
enlarged left atrium and normal left ventricular
function and valvular structures. Following this
diagnosis of paroxysmal AF, he was treated with
apixaban and bisoprolol.
HOW DO WE MANAGE AF SECONDARY
TO IBRUTINIB?
The main considerations when managing AF are:
1. Rhythm control versus rate control
2. Anticoagulation
HOW DO WE DECIDE ON RATE CONTROL
VERSUS RHYTHM CONTROL?
There is a paucity of randomized controlled trial data
addressing the question of rate versus rhythm control
in patients with hematologic malignancy. We typi-
cally advise a rate control strategy, because mainte-
nance of sinus rhythm may be less likely in patients
being treated with proarrhythmogenic cancer thera-
pies. In specific populations, rhythm control may be
more appropriate; for example, in young patients
without structural heart disease who have completed
proarrhythmogenic therapy or patients who are un-
able to tolerate their symptom load. When using a
rate control strategy, we advise beta-blockers as first-
line therapy. This is due to interactions between
ibrutinib and calcium channel blockers (diltiazem and
verapamil), which have a CYP3A4 inhibitory effect
resulting in increased levels of ibrutinib and resultant
exacerbation of AF and bleeding. Digoxin is also
known to have P-glycoprotein interactions resulting
in increased plasma levels of digoxin and so should be
avoided whenever possible. If there are no other op-
tions, we suggest a lower dose of digoxin to be given
6 h before or after ibrutinib (2).
In our case, a decision was made for a rate control
strategy based on: 1) patient’s age; 2) need for
ongoing Ibrutinib treatment; 3) low symptom burden
reported by the patient; and 4) left atrial enlargement
on echocardiogram suggesting that a rhythm control
strategy was less likely to be successful.
HOW DO WE MANAGE ANTICOAGULATION?
The decision to start anticoagulation includes
consideration of stroke and bleeding risk, and the
most validated and commonly utilized risk stratifi-
cation strategy includes the CHA2DS2-VASc and HAS-
BLED scores. However, these scoring systems do not
consider cancer-specific high-risk bleeding featuressuch as intracranial metastasis, severe
thrombocytopenia, and actively bleeding
high-risk malignancies. This was recognized
in a European Society of Cardiology position
paper that advised that treatment should not
hinge solely on the utility of scoring systems
derived from and validated in the general
population (3). Therefore, treatment de-
cisions should be personalized to the indi-
vidual patient and cancer type.
Vitamin K antagonists such as warfarin
have traditionally been used for stroke prevention in
patients with both AF and cancer. Close monitoring is
required, and the likelihood of achieving optimal
time in the therapeutic window can be reduced dur-
ing cancer treatment. Therefore, low molecular
weight heparin (LMWH) may be a more suitable op-
tion in these circumstances.
Injectable subcutaneous LMWH is a frequently
used treatment option due to a large evidence base
supporting its utility in the treatment of venous
thromboembolism in cancer patients. Studies derived
from patients treated in everyday practice have
shown that over 50% of treated patients with AF and
cancer are on LMWH, but with a large proportion on
prophylactic doses rather than treatment doses (5).
The introduction of the direct oral anticoagulants
(DOACs) has resulted in a paradigm shift in the
management of AF. However, the role of DOACs in AF
patients with cancer is less clear, because many of the
pivotal trials for these medications excluded cancer
patients and/or patients with limited life expec-
tancies. A 2020 meta-analysis of randomized
controlled trials and cohort studies that included
subgroup analyses of cancer patients from the
ROCKET-AF (Rivaroxaban Once Daily Oral Direct
Factor Xa Inhibitor Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation), ENGAGE AF-TIMI 48
(Effective Anticoagulation With Factor Xa Next Gen-
eration in Atrial Fibrillation-Thrombolysis In
Myocardial Infarction 48), and ARISTOTLE (Apixaban
for the Prevention of Stroke in Subjects With Atrial
Fibrillation) trials demonstrated that compared to
vitamin K antagonists, DOACs have a similar inci-
dence of systemic embolism (odds ratio [OR]: 0.70;
p ¼ 0.11), stroke (OR: 0.71; p ¼ 0.42), venous throm-
boembolism (OR: 0.91; p ¼ 0.86) and all cause death
(OR: 1.02; p ¼ 0.13). The rate of intracranial bleeding
was significantly lower with DOACs (OR: 0.11;
p ¼ 0.01) (6). Furthermore, data from 16,096 AF pa-
tients with cancer treated with DOACs demonstrated
that these patients experienced lower or similar rates
of bleeding and stroke as compared with warfarin
FIGURE 1 The ABC Pathway Applied to Oncology Patients
The ABC (AF Better Care) pathway can be used to provide holistic management of atrial fibrillation (AF) patients. Step A focuses on avoiding
stroke via utilization of the CHA2DS2-VASc score and treatment of modifiable bleeding risk factors via the HAS-BLED score. Step B focuses on
symptom control in AF and the decision between rate versus rhythm control. Step C focuses on management of modifiable cardiovascular risk
factors. Hb ¼ hemoglobin; INR ¼ international normalized ratio.
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142users (1). However, given that DOACs are relatively
newer medications, there is less information on their
interactions with cancer therapies, and this should be
noted before their use.
SPECIAL CONSIDERATIONS WITH
ANTICOAGULATION AND IBRUTINIB
The management of ibrutinib-induced AF is compli-
cated by: 1) an increased risk of bleeding due to in-
hibition of collagen induced platelet aggregation (7);
and 2) drug pharmacokinetics owing to metabolism
by cytochrome PCYP3A4 and P-glycoprotein inhibi-
tion. Ibrutinib is known to interact with several of the
medications utilized in the management of AF
including calcium channel blockers, digoxin, amio-
darone, and DOACs (7).There are limited anticoagulation options in this
cohort, with most of the evidence derived from small
retrospective studies. Further complicating anti-
coagulation is the increased bleeding risk inherent to
ibrutinib therapy. It is well recognized that up to 44%
of patients on ibrutinib experience some form of
bleeding event during their treatment course (7).
Most bleeding is minor and limited to events such as
epistaxis, hematuria, ecchymosis, and mucosal
bleeding. However, major bleeding has been seen in
up to 7% of patients after a year (7). Therefore, pa-
tients should be counseled with regards to bleeding
risks before ibrutinib initiation. Furthermore, there is
strong evidence implicating concurrent ibrutinib and
warfarin therapy with an increased risk of intracere-
bral bleeding, particularly in the mantle cell popula-
tion (7). This is possibly mediated via CYP3A4 drug
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143interactions leading to higher levels of warfarin.
Therefore, warfarin is generally reserved for patients
previously on warfarin before initiation of ibrutinib
and unable to take DOACs. Generally, a DOAC is rec-
ommended with close monitoring for any side effects.
We recommend utility of a factor Xa inhibitor (apix-
aban, rivaroxaban, edoxoban) and avoidance of the
direct thrombin inhibitor dabigatran due to P-glyco-
protein interactions. We advise starting a DOAC at a
low dose for 10 to 14 days in patients with HASBLED
scores $3 before increasing it to a maintenance dose
(7). In patients at even higher risk of bleeding, we
would advise a short-term reduction in the dose of
ibrutinib until the patient is stabilized. Alternatively,
LMWH is also an option in some patient groups. In the
event of a clinically significant major bleeding event,
we advise discontinuation of ibrutinib and trans-
fusing the patient with platelets  red blood cells
until the bleeding event has terminated.
In view of the limited treatment options and the
increased risk of bleeding in this patient cohort, we
recommend that patients with ibrutinib-induced AF
are managed by a cardio-oncologist. Populations at
high risk of AF (elderly, those with cardiovascular
disease, chronic lung disease, and cardiomyopathy)
should undergo baseline cardiovascular risk stratifi-
cation and aggressive risk factor management before
starting ibrutinib (2,8). We suggest that oncologists
are aware of the importance of cardiovascular disease
risk factor management and refer to a cardio-
oncologist as needed.
CASE CONTINUED
Six months later, the patient was tolerating his anti-
coagulation and beta-blocker, and was asymptomatic.
It is important to follow patients with new AF. This
is particularly important if the proarrhythmogenic
treatment is continuing because their symptom load
may increase. If this patient started complaining of
increasing palpitations and shortness of breath, it
would be prudent to increase his rate control medi-
cation. If his symptoms were refractory to maximal
medical therapy, he would then be considered for a
rhythm control strategy, which can include medica-
tions, or more invasive management such as atrio-
ventricular node ablation and pacemaker insertion or
radiofrequency ablation. If a rhythm control strategy
is pursued, it is advisable to avoid CYP3A4 inhibitors
such as amiodarone, diltiazem, and verapamil.
Generally, it is accepted that Class 1B and 1C antiar-
rhythmic drugs are the least likely to cause drug–druginteractions with ibrutinib (9). An electrical cardio-
version strategy can also be considered. An alterna-
tive rhythm control strategy could potentially involve
acalabrutinib. This is a second-generation BTK in-
hibitor that is more selective and has thus far
demonstrated lower rates of AF and bleeding (10).
Our treatment decisions throughout the case were
guided by the AF Better Care (ABC) pathway, which
our group has pioneered (Figure 1). The ABC pathway
proposes a streamlined approach to holistic AF man-
agement that is applicable to primary and secondary
care: A, Avoid stroke/Anticoagulation; B, Better
symptom management, with patient-centered symp-
tom-directed decisions on rate or rhythm control; and
C, Cardiovascular risk factor and Comorbidity man-
agement, including addressing lifestyle factors.
CONCLUSIONS
AF is a common condition seen in the cancer popu-
lation due to multiple shared risk factors and proar-
rhythmogenic cancer treatments. The main decisions
in the treatment of AF are: 1) choice of anti-
coagulation; and 2) rate versus rhythm control. In
both these aspects, there is a paucity of evidence
guiding clinical practice in cancer patients. Further-
more, there are a plethora of pitfalls including a
higher risk of bleeding and drug interactions. Oncol-
ogists should take a pragmatic case-by-case approach
and use a multidisciplinary team that incorporates
cardio-oncologists to generate treatment decisions
with an acceptable risk profile to the patient while
modifying risk factors. Moving forward, high-quality
trials are required to generate evidence-based guid-
ance for clinicians on the best management strategies
in this population.
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